Trial Profile
A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 11 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.